Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design

Journal of the National Cancer Institute

Volumn 100, Issue 20, 2008, Pages 1432-1438

  Pepe, Margaret S ^a   Feng, Ziding ^a   Janes, Holly ^a   Bossuyt, Patrick M ^b   Potter, John D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CALIBRATION; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE MARKER; EVALUATION; HUMAN; NOTE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; ARTICLE; CLASSIFICATION; METHODOLOGY; NEOPLASM; PREDICTION AND FORECASTING;

CASE-CONTROL STUDIES; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 54049129625     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn326     Document Type: Note

References (22)

1. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol. 2007;60(12):1205-1219.
2. Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ. 2002;324(7335):477-480.
3. Hernandez-Aguado I. The winding road towards evidence based diagnoses. J Epidemiol Community Health. 2002;56(5):323-325.
4. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999;18(15):1905-1942.
5. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23(9):2020-2027.
6. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054-1061.
7. Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials. 2006;3(1):43-56.
8. Alonzo TA, Pepe MS. Using a combination of reference tests to assess the accuracy of a new diagnostic test. Stat Med. 1999;18(22):2987-3003.
9. Janes H, Pepe MS. Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. Biometrics. 2008;64(1):1-9.
10. Janes H, Pepe M. Adjusting for covariates in studies of diagnostic, screening or prognostic markers: an old concept in a new setting. Am J Epidemiol. 2008;168(1):89-97.
11. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692-1702.
12. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98(17):1183-1192.
13. Shaw P, Pepe M, Alonzo T, Etzioni R. Methods for assessing improvement in specificity when a biomarker is combined with a standard screening test. Stat Biopharm Res. In press.
14. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York, NY: Springer-Verlag; 2007.
15. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2005;23(29):7332-7341.
16. Ellenberg S, Fleming T, DeMets D. Data Monitoring Committees in Clinical Trials. New York: John Wiley and Sons; 2002.
17. Pepe M, Feng Z, Longton G, Koopmeiners J. Estimating Sensitivity and Specificity from a Phase 2 Biomarker Study That Allows for Early Termination. UW Biostatistics Working Paper Series; 2007.
18. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2003.
19. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol. 2002;2:4.
20. Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge: Cambridge University Press; 2001.
21. Feng Z, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics. 2004;5(6):709-719.
22. Brenner DE, Normolle DP. Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1918-1920.